Considering that CLL is characterized by a variable clinical and laboratory presentation and prognosis and that the majority of previous studies have enrolled a few CLL patients (ranged from 10–25), the contribution of TACI expression in the disease phenotype remains as yet obscure. The gene discussed is TNFRSF13B; the disease is B-cell chronic lymphocytic leukemia.